Trial Profile
Phase II clinical trial of neuroprotection by cannabinoids in Huntington disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2022
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary)
- Indications Huntington's disease
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms SAT-HD
- Sponsors Jazz Pharmaceuticals Inc
- 30 Dec 2011 GW Pharmaceuticals added as trial sponsor as reported by ClinicalTrials.gov.
- 30 Dec 2011 Actual patient number (25) added as reported by ClinicalTrials.gov.
- 30 Dec 2011 Planned end date changed from 5 Apr 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.